fruit loop
Inactive
We knew it, but it still burns my behind. All this insistence on vaxing girls at 12 "before they're sexually active" so they'd have lifetime protection and be "one less".....
This vax is extremely expensive (about $300 per prick) and if it wears off within 3 years - how many women will really be protected???
Remember how it was supposed to be LIFETIME? And they want to vax girls at 12 "before they become sexually active"?
The average girl becomes sexually active at 17. This vax will have worn off. If it's only good for three years.....and at $300 for the injections....how many women will REALLY be protected???
http://www.cnn.com/2007/HEALTH/condi...eut/index.html
Cervical cancer vaccine protects for at least three years
POSTED: 10:01 a.m. EDT, May 10, 2007
Adjust font size:
BOSTON, Massachusetts (Reuters) -- Merck's Gardasil vaccine protects against cervical cancer caused by a sexually transmitted wart virus for at least three years and also prevents lesions that can grow into vaginal and vulvar cancer, according to two studies published on Wednesday.
And a third study concluded the virus may cause a significant number of throat cancers in men and women, probably due to oral sex.
"Investigators in these trials have hit their mark soundly: The vaccine showed significant efficacy against anogenital and cervical lesions," Dr. George Sawaya and Dr. Karen Smith-McCune of the University of California, San Francisco, wrote in a commentary in the New England Journal of Medicine, where the studies appear.
"The vaccine also appears safe."
Gardasil protects against the four strains of the human papilloma virus, or HPV, that cause 70 percent of cases of cervical cancer.
One team of international researchers, led by Dr. Laura Koutsky of the University of Washington, studied 12,167 women aged 15 to 26 in 13 countries. Half got three doses of the vaccine and half got placebo shots.
The vaccine prevented pre-cancerous lesions in 98 percent of the women who had never been infected with the HPV-16 and HPV-18 strains over three years, Koutsky's team reported.
Dr. Suzanne Garland of the Royal Women's Hospital in Melbourne, Australia, and colleagues tested 5,455 women aged 16 to 24 and found the vaccine was 100 percent effective against the lesions that can develop into cervical, vulvar, vaginal and anal cancers.
Dr. Maura Gillison of Johns Hopkins University and colleagues studied 100 patients with oral or throat cancer and compared them to 200 healthy people and found those who had six or more oral sex partners had a high risk of the cancer.
They found evidence of HPV-16 in 72 percent of the tumors.
Controversial vaccine
The U.S. Centers for Disease Control and Prevention has recommended the vaccine for 30 million women and girls aged 11 to 26.
But state proposals for mandatory vaccination have met with resistance, even though all allow parents to exclude their child.
"Such a slight burden on parents can hardly justify backing away from the most effective means of protecting a generation of women, and in particular, poor and disadvantaged women, from the scourge of cervical cancer," Alta Charo, a bioethicist at the University of Wisconsin, Madison, wrote in a commentary.
The vaccine does not work after a woman is already infected, and HPV is very common. By age 14 to 19, one-quarter of U.S. teens are already infected with at least one strain.
"Delaying vaccination may mean that many women will miss an opportunity for long-lasting protection," Sawaya and Smith-McCune wrote.
Cervical cancer is the second most common type of tumor in women and the leading cause of cancer deaths in some countries. Such tumors kill about 300,000 women worldwide each year, mostly in developing countries.
The lesions that lead to cervical cancer can be detected with a Pap smear and removed before they become tumors, and experts stress that vaccinated women will still need to get the smears regularly.
The vaccine's cost -- $360 for three doses over six months -- is too high for women in poorer countries where HPV is the biggest threat, some experts have noted.
GlaxoSmithKline is also developing an HPV vaccine called Cervarix. A study released in April showed it protects women for more than 5½ years.
This vax is extremely expensive (about $300 per prick) and if it wears off within 3 years - how many women will really be protected???
Remember how it was supposed to be LIFETIME? And they want to vax girls at 12 "before they become sexually active"?
The average girl becomes sexually active at 17. This vax will have worn off. If it's only good for three years.....and at $300 for the injections....how many women will REALLY be protected???
http://www.cnn.com/2007/HEALTH/condi...eut/index.html
Cervical cancer vaccine protects for at least three years
POSTED: 10:01 a.m. EDT, May 10, 2007
Adjust font size:
BOSTON, Massachusetts (Reuters) -- Merck's Gardasil vaccine protects against cervical cancer caused by a sexually transmitted wart virus for at least three years and also prevents lesions that can grow into vaginal and vulvar cancer, according to two studies published on Wednesday.
And a third study concluded the virus may cause a significant number of throat cancers in men and women, probably due to oral sex.
"Investigators in these trials have hit their mark soundly: The vaccine showed significant efficacy against anogenital and cervical lesions," Dr. George Sawaya and Dr. Karen Smith-McCune of the University of California, San Francisco, wrote in a commentary in the New England Journal of Medicine, where the studies appear.
"The vaccine also appears safe."
Gardasil protects against the four strains of the human papilloma virus, or HPV, that cause 70 percent of cases of cervical cancer.
One team of international researchers, led by Dr. Laura Koutsky of the University of Washington, studied 12,167 women aged 15 to 26 in 13 countries. Half got three doses of the vaccine and half got placebo shots.
The vaccine prevented pre-cancerous lesions in 98 percent of the women who had never been infected with the HPV-16 and HPV-18 strains over three years, Koutsky's team reported.
Dr. Suzanne Garland of the Royal Women's Hospital in Melbourne, Australia, and colleagues tested 5,455 women aged 16 to 24 and found the vaccine was 100 percent effective against the lesions that can develop into cervical, vulvar, vaginal and anal cancers.
Dr. Maura Gillison of Johns Hopkins University and colleagues studied 100 patients with oral or throat cancer and compared them to 200 healthy people and found those who had six or more oral sex partners had a high risk of the cancer.
They found evidence of HPV-16 in 72 percent of the tumors.
Controversial vaccine
The U.S. Centers for Disease Control and Prevention has recommended the vaccine for 30 million women and girls aged 11 to 26.
But state proposals for mandatory vaccination have met with resistance, even though all allow parents to exclude their child.
"Such a slight burden on parents can hardly justify backing away from the most effective means of protecting a generation of women, and in particular, poor and disadvantaged women, from the scourge of cervical cancer," Alta Charo, a bioethicist at the University of Wisconsin, Madison, wrote in a commentary.
The vaccine does not work after a woman is already infected, and HPV is very common. By age 14 to 19, one-quarter of U.S. teens are already infected with at least one strain.
"Delaying vaccination may mean that many women will miss an opportunity for long-lasting protection," Sawaya and Smith-McCune wrote.
Cervical cancer is the second most common type of tumor in women and the leading cause of cancer deaths in some countries. Such tumors kill about 300,000 women worldwide each year, mostly in developing countries.
The lesions that lead to cervical cancer can be detected with a Pap smear and removed before they become tumors, and experts stress that vaccinated women will still need to get the smears regularly.
The vaccine's cost -- $360 for three doses over six months -- is too high for women in poorer countries where HPV is the biggest threat, some experts have noted.
GlaxoSmithKline is also developing an HPV vaccine called Cervarix. A study released in April showed it protects women for more than 5½ years.
Only 98% effective in women who had NEVER even been infected with the HPV virus??
especially if you've never been infected with HPV...
